Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Liquid biopsy in ovarian cancer: the potential of circulating miRNAs and exosomes.

Giannopoulou L, Zavridou M, Kasimir-Bauer S, Lianidou ES.

Transl Res. 2018 Oct 12. pii: S1931-5244(18)30186-5. doi: 10.1016/j.trsl.2018.10.003. [Epub ahead of print] Review.

PMID:
30391474
2.

ESR1 methylation in primary tumors and paired circulating tumor DNA of patients with high-grade serous ovarian cancer.

Giannopoulou L, Mastoraki S, Buderath P, Strati A, Pavlakis K, Kasimir-Bauer S, Lianidou ES.

Gynecol Oncol. 2018 Aug;150(2):355-360. doi: 10.1016/j.ygyno.2018.05.026. Epub 2018 May 26.

PMID:
29807696
3.

Multiplex Gene Expression Profiling of In Vivo Isolated Circulating Tumor Cells in High-Risk Prostate Cancer Patients.

Markou A, Lazaridou M, Paraskevopoulos P, Chen S, Świerczewska M, Budna J, Kuske A, Gorges TM, Joosse SA, Kroneis T, Zabel M, Sedlmayr P, Alix-Panabières C, Pantel K, Lianidou ES.

Clin Chem. 2018 Feb;64(2):297-306. doi: 10.1373/clinchem.2017.275503. Epub 2017 Nov 9.

PMID:
29122836
4.

Liquid biopsy: An emerging prognostic and predictive tool in Head and Neck Squamous Cell Carcinoma (HNSCC). Focus on Circulating Tumor Cells (CTCs).

Economopoulou P, Kotsantis I, Kyrodimos E, Lianidou ES, Psyrri A.

Oral Oncol. 2017 Nov;74:83-89. doi: 10.1016/j.oraloncology.2017.09.012. Epub 2017 Oct 2. Review.

PMID:
29103757
5.

Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA.

Giannopoulou L, Kasimir-Bauer S, Lianidou ES.

Clin Chem Lab Med. 2018 Jan 26;56(2):186-197. doi: 10.1515/cclm-2017-0019. Review.

6.

Exosomes: A Cancer Theranostics Road Map.

Panagiotara A, Markou A, Lianidou ES, Patrinos GP, Katsila T.

Public Health Genomics. 2017;20(2):116-125. doi: 10.1159/000478253. Epub 2017 Jul 20. Review.

7.

miRNA-21 as a novel therapeutic target in lung cancer.

Markou A, Zavridou M, Lianidou ES.

Lung Cancer (Auckl). 2016 Mar 2;7:19-27. doi: 10.2147/LCTT.S60341. eCollection 2016. Review.

8.

RASSF1A promoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA.

Giannopoulou L, Chebouti I, Pavlakis K, Kasimir-Bauer S, Lianidou ES.

Oncotarget. 2017 Mar 28;8(13):21429-21443. doi: 10.18632/oncotarget.15249.

9.

Development and validation of a multiplex methylation specific PCR-coupled liquid bead array for liquid biopsy analysis.

Parisi C, Mastoraki S, Markou A, Strati A, Chimonidou M, Georgoulias V, Lianidou ES.

Clin Chim Acta. 2016 Oct 1;461:156-64. doi: 10.1016/j.cca.2016.08.003. Epub 2016 Aug 7.

PMID:
27510924
10.

Gene expression profiling and DNA methylation analyses of CTCs.

Lianidou ES.

Mol Oncol. 2016 Mar;10(3):431-42. doi: 10.1016/j.molonc.2016.01.011. Epub 2016 Feb 5. Review.

11.

The Role of CTCs as Tumor Biomarkers.

Lianidou ES, Markou A, Strati A.

Adv Exp Med Biol. 2015;867:341-67. doi: 10.1007/978-94-017-7215-0_21. Review.

PMID:
26530376
12.

Prognostic role of APC and RASSF1A promoter methylation status in cell free circulating DNA of operable gastric cancer patients.

Balgkouranidou I, Matthaios D, Karayiannakis A, Bolanaki H, Michailidis P, Xenidis N, Amarantidis K, Chelis L, Trypsianis G, Chatzaki E, Lianidou ES, Kakolyris S.

Mutat Res. 2015 Aug;778:46-51. doi: 10.1016/j.mrfmmm.2015.05.002. Epub 2015 Jun 11.

PMID:
26073472
13.

Molecular characterization of circulating tumor cells: Holy Grail for personalized cancer treatment?

Lianidou ES.

Clin Chem. 2014 Oct;60(10):1249-51. doi: 10.1373/clinchem.2014.230144. Epub 2014 Aug 20. No abstract available.

14.

Breast cancer metastasis suppressor-1 promoter methylation in cell-free DNA provides prognostic information in non-small cell lung cancer.

Balgkouranidou I, Chimonidou M, Milaki G, Tsarouxa EG, Kakolyris S, Welch DR, Georgoulias V, Lianidou ES.

Br J Cancer. 2014 Apr 15;110(8):2054-62. doi: 10.1038/bjc.2014.104. Epub 2014 Mar 18.

15.

Circulating tumor cells as promising novel biomarkers in solid cancers.

Lianidou ES, Strati A, Markou A.

Crit Rev Clin Lab Sci. 2014 Jun;51(3):160-71. doi: 10.3109/10408363.2014.896316. Epub 2014 Mar 19. Review.

PMID:
24641350
16.

Circulating tumor cell isolation: a marathon race worth running.

Lianidou ES.

Clin Chem. 2014 Feb;60(2):287-9. doi: 10.1373/clinchem.2013.216010. Epub 2013 Dec 9. No abstract available.

17.

Advances in circulating tumor cells (ACTC): from basic research to clinical practice.

Lianidou ES, Mavroudis D, Pantel K.

Breast Cancer Res. 2013 Dec 5;15(6):319. doi: 10.1186/bcr3582.

18.

Quantification of circulating miRNAs in plasma: effect of preanalytical and analytical parameters on their isolation and stability.

Sourvinou IS, Markou A, Lianidou ES.

J Mol Diagn. 2013 Nov;15(6):827-34. doi: 10.1016/j.jmoldx.2013.07.005. Epub 2013 Aug 27.

PMID:
23988620
19.

Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer.

Lianidou ES, Mavroudis D, Georgoulias V.

Br J Cancer. 2013 Jun 25;108(12):2426-32. doi: 10.1038/bjc.2013.265. Epub 2013 Jun 11. Review.

20.

Breast cancer metastasis suppressor-1 promoter methylation in primary breast tumors and corresponding circulating tumor cells.

Chimonidou M, Kallergi G, Georgoulias V, Welch DR, Lianidou ES.

Mol Cancer Res. 2013 Oct;11(10):1248-57. doi: 10.1158/1541-7786.MCR-13-0096. Epub 2013 Jun 6.

21.

Comparison of three molecular assays for the detection and molecular characterization of circulating tumor cells in breast cancer.

Strati A, Kasimir-Bauer S, Markou A, Parisi C, Lianidou ES.

Breast Cancer Res. 2013 Mar 7;15(2):R20. doi: 10.1186/bcr3395.

22.

Lung cancer epigenetics: emerging biomarkers.

Balgkouranidou I, Liloglou T, Lianidou ES.

Biomark Med. 2013 Feb;7(1):49-58. doi: 10.2217/bmm.12.111. Review.

23.

SOX17 promoter methylation in circulating tumor cells and matched cell-free DNA isolated from plasma of patients with breast cancer.

Chimonidou M, Strati A, Malamos N, Georgoulias V, Lianidou ES.

Clin Chem. 2013 Jan;59(1):270-9. doi: 10.1373/clinchem.2012.191551. Epub 2012 Nov 7.

24.

A closed-tube methylation-sensitive high resolution melting assay (MS-HRMA) for the semi-quantitative determination of CST6 promoter methylation in clinical samples.

Dimitrakopoulos L, Vorkas PA, Georgoulias V, Lianidou ES.

BMC Cancer. 2012 Oct 22;12:486. doi: 10.1186/1471-2407-12-486.

25.

Molecular characterization of circulating tumor cells in breast cancer: challenges and promises for individualized cancer treatment.

Lianidou ES, Markou A, Strati A.

Cancer Metastasis Rev. 2012 Dec;31(3-4):663-71. doi: 10.1007/s10555-012-9366-8. Review.

PMID:
22692478
26.

Molecular assays for the detection and characterization of CTCs.

Lianidou ES, Markou A.

Recent Results Cancer Res. 2012;195:111-23. doi: 10.1007/978-3-642-28160-0_10. Review.

PMID:
22527499
27.

Circulating tumor cells--new challenges ahead.

Lianidou ES.

Clin Chem. 2012 May;58(5):805-7. doi: 10.1373/clinchem.2011.180646. Epub 2012 Feb 21. No abstract available.

28.

Development of a multiplexed PCR-coupled liquid bead array assay for vascular endothelial growth factor (VEGF) splice variants.

Parisi C, Markou A, Lianidou ES.

Clin Biochem. 2012 Apr;45(6):475-82. doi: 10.1016/j.clinbiochem.2012.01.025. Epub 2012 Feb 11.

PMID:
22330939
29.

Circulating tumor cells as emerging tumor biomarkers in breast cancer.

Lianidou ES, Markou A.

Clin Chem Lab Med. 2011 Oct;49(10):1579-90. doi: 10.1515/CCLM.2011.628. Epub 2011 Jul 29. Review.

PMID:
21801030
30.

Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges.

Lianidou ES, Markou A.

Clin Chem. 2011 Sep;57(9):1242-55. doi: 10.1373/clinchem.2011.165068. Epub 2011 Jul 22. Review.

31.

DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells.

Chimonidou M, Strati A, Tzitzira A, Sotiropoulou G, Malamos N, Georgoulias V, Lianidou ES.

Clin Chem. 2011 Aug;57(8):1169-77. doi: 10.1373/clinchem.2011.165902. Epub 2011 Jun 23.

32.

Molecular characterization of circulating tumor cells in breast cancer by a liquid bead array hybridization assay.

Markou A, Strati A, Malamos N, Georgoulias V, Lianidou ES.

Clin Chem. 2011 Mar;57(3):421-30. doi: 10.1373/clinchem.2010.154328. Epub 2011 Jan 18.

33.

What's new on circulating tumor cells? A meeting report.

Lianidou ES, Mavroudis D, Sotiropoulou G, Agelaki S, Pantel K.

Breast Cancer Res. 2010;12(4):307. doi: 10.1186/bcr2601. Epub 2010 Jul 23.

34.

PIK3CA hotspot mutation scanning by a novel and highly sensitive high-resolution small amplicon melting analysis method.

Vorkas PA, Poumpouridou N, Agelaki S, Kroupis C, Georgoulias V, Lianidou ES.

J Mol Diagn. 2010 Sep;12(5):697-704. doi: 10.2353/jmoldx.2010.100008. Epub 2010 Jul 8. Erratum in: J Mol Diagn. 2013 Sep;15(5):730.

35.

Hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients.

Kallergi G, Markomanolaki H, Giannoukaraki V, Papadaki MA, Strati A, Lianidou ES, Georgoulias V, Mavroudis D, Agelaki S.

Breast Cancer Res. 2009;11(6):R84. doi: 10.1186/bcr2452. Epub 2009 Nov 17.

36.

Mutation scanning of exon 20 of the BRCA1 gene by high-resolution melting curve analysis.

Vorkas PA, Christopoulos K, Kroupis C, Lianidou ES.

Clin Biochem. 2010 Jan;43(1-2):178-85. doi: 10.1016/j.clinbiochem.2009.08.024. Epub 2009 Sep 9.

PMID:
19747471
37.
38.

Methylation of cystatin M promoter is associated with unfavorable prognosis in operable breast cancer.

Kioulafa M, Balkouranidou I, Sotiropoulou G, Kaklamanis L, Mavroudis D, Georgoulias V, Lianidou ES.

Int J Cancer. 2009 Dec 15;125(12):2887-92. doi: 10.1002/ijc.24686.

39.

Prognostic significance of RASSF1A promoter methylation in operable breast cancer.

Kioulafa M, Kaklamanis L, Mavroudis D, Georgoulias V, Lianidou ES.

Clin Biochem. 2009 Jul;42(10-11):970-5. doi: 10.1016/j.clinbiochem.2009.04.003. Epub 2009 Apr 15.

PMID:
19374895
40.

Kallikrein 10 (KLK10) methylation as a novel prognostic biomarker in early breast cancer.

Kioulafa M, Kaklamanis L, Stathopoulos E, Mavroudis D, Georgoulias V, Lianidou ES.

Ann Oncol. 2009 Jun;20(6):1020-5. doi: 10.1093/annonc/mdn733. Epub 2009 Jan 15.

PMID:
19150938
41.

Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR.

Markou A, Tsaroucha EG, Kaklamanis L, Fotinou M, Georgoulias V, Lianidou ES.

Clin Chem. 2008 Oct;54(10):1696-704. doi: 10.1373/clinchem.2007.101741. Epub 2008 Aug 21.

42.

Endothelin system and atrial fibrillation post-cardiac surgery.

Kolettis TM, Kyriakides ZS, Zygalaki E, Kyrzopoulos S, Kaklamanis L, Nikolaou N, Lianidou ES, Kremastinos DT.

J Interv Card Electrophysiol. 2008 Apr;21(3):203-8. doi: 10.1007/s10840-008-9206-5. Epub 2008 Feb 9.

PMID:
18264746
43.

Asymmetric real-time PCR detection of BRCA1 5382insC mutation by melting curve analysis in the LightCycler.

Kroupis C, Christopoulos K, Devetzoglou M, Tsiagas I, Lianidou ES.

Clin Chim Acta. 2008 Apr;390(1-2):141-4. doi: 10.1016/j.cca.2007.12.024. Epub 2008 Jan 17.

PMID:
18242166
44.

Expression profile of total VEGF, VEGF splice variants and VEGF receptors in the myocardium and arterial vasculature of diabetic and non-diabetic patients with coronary artery disease.

Zygalaki E, Kaklamanis L, Nikolaou NI, Kyrzopoulos S, Houri M, Kyriakides Z, Lianidou ES, Kremastinos DT.

Clin Biochem. 2008 Jan;41(1-2):82-7. Epub 2007 Sep 21.

PMID:
17961532
46.

Real-time RT-PCR quantification of human telomerase reverse transcriptase splice variants in tumor cell lines and non-small cell lung cancer.

Mavrogiannou E, Strati A, Stathopoulou A, Tsaroucha EG, Kaklamanis L, Lianidou ES.

Clin Chem. 2007 Jan;53(1):53-61. Epub 2006 Nov 27.

47.

Detection of Mammaglobin A-mRNA-positive circulating tumor cells in peripheral blood of patients with operable breast cancer with nested RT-PCR.

Ntoulia M, Stathopoulou A, Ignatiadis M, Malamos N, Mavroudis D, Georgoulias V, Lianidou ES.

Clin Biochem. 2006 Sep;39(9):879-87. Epub 2006 Jul 20.

PMID:
16925986
48.

HER-2 DNA quantification of paraffin-embedded breast carcinomas with LightCycler real-time PCR in comparison to immunohistochemistry and chromogenic in situ hybridization.

Ntoulia M, Kaklamanis L, Valavanis C, Kafousi M, Stathopoulos E, Arapantoni P, Mavroudis D, Georgoulias V, Lianidou ES.

Clin Biochem. 2006 Sep;39(9):942-6. Epub 2006 Jul 13.

PMID:
16916505
49.

Presence of high-risk human papillomavirus sequences in breast cancer tissues and association with histopathological characteristics.

Kroupis C, Markou A, Vourlidis N, Dionyssiou-Asteriou A, Lianidou ES.

Clin Biochem. 2006 Jul;39(7):727-31. Epub 2006 Jun 15.

PMID:
16780823
50.

Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients.

Xenidis N, Perraki M, Kafousi M, Apostolaki S, Bolonaki I, Stathopoulou A, Kalbakis K, Androulakis N, Kouroussis C, Pallis T, Christophylakis C, Argyraki K, Lianidou ES, Stathopoulos S, Georgoulias V, Mavroudis D.

J Clin Oncol. 2006 Aug 10;24(23):3756-62. Epub 2006 Jun 12.

PMID:
16769987

Supplemental Content

Loading ...
Support Center